Trials / Completed
CompletedNCT06705504
A Real-world Study of Effectiveness and Safety in HR+/HER2- Breast Cancer Patients Treated With Ribociclib or Alpelisib
Real-world Effectiveness and Safety in HR+/HER2- Advanced or Metastatic BC Patients Treated With Ribociclib or Alpelisib: A European Non-interventional Retrospective Study (REASSURE)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 435 (actual)
- Sponsor
- Novartis · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
This study was a multinational and multicenter cohort study of patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced or metastatic breast cancer (aBC/mBC) treated with ribociclib or alpelisib between the period of 01 January 2018 and 30 September 2021. Patients who were receiving active treatment for malignancies other than BC or participating in a clinical trial were excluded. This study was conducted retrospectively with secondary use of data.
Conditions
Timeline
- Start date
- 2021-06-11
- Primary completion
- 2023-11-30
- Completion
- 2023-11-30
- First posted
- 2024-11-26
- Last updated
- 2024-11-26
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT06705504. Inclusion in this directory is not an endorsement.